About Us

Apobiologix: Focused on the Development and Distribution of Biosimilar Therapies

Invention Is Not the Only Innovation.

Traditional companies focus their innovative efforts on the discovery of new drugs that save and improve lives. Apobiologix sees a need to go further: to create sustainable health care that doesn't sacrifice quality or patient support. That's why biosimilars also require innovation.

Image of a chemist.

Apobiologix is focused on the development of biosimilars that combine the quality and value you need with the level of comprehensive support you expect.

Because at Apobiologix, we don't believe that innovation stops at invention.

Experienced in the Development and Marketing of Biosimilars

Apobiologix is a company with over 10 years of biosimilar development history and over 5 years of combined biosimilar post-marketing experience in Canada and the EU.

Apobiologix successfully launched Grastofil in Canada in early 2016. Grastofil was the first biosimilar filgrastim approved by Health Canada for the same indications of use as the reference biologic. Grastofil has been widely adopted by payers across the country – both public and private. Patients prescribed Grastofil are supported by Apobiologix's ANSWERS™ program (patient support program). In 2018, Apobiologix's Lapelga became the first pegfilgrastim biosimilar to receive approval from Health Canada. This is the first approval of biosimilar pegfilgrastim in Canada and in the world.

Timeline of Apobiologix's initiation and product releases.

Invention is not the only innovation.

Apobiologix logo

2400 North Commerce Parkway,
Suite 300,
Weston, Florida 33326



Grastofil® is a registered trademark of Apotex Technologies Inc.
Lapelga™ is a trademark of Apotex Technologies Inc.
ANSWERS™ is a trademark of Apotex Technologies Inc.
Neupogen® and Neulasta® are registered trademarks of Amgen.